Table 1.

Signalment and existing treatments in 33 dogs undergoing assessment of plasma angiotensin‐converting enzyme 2 (ACE2) activity, including healthy dogs and dogs with congestive heart failure (CHF) because of degenerative mitral valve disease. Data shown as count or median (interquartile range)

	Healthy	CHF	P
N	18	15
Sex (F/M)	10/8	9/6	.62
Age (years)	8 (6.8‐10)	12 (11‐14)	.0001
Body weight (kg)	11.1 (9.1‐24.5)	8.1 (5.6‐11.4)	.02
Breeds	Mixed breed (n, 5)	Mixed breed (n, 3)
	Boston Terrier (n, 2)	Shih Tzu (n, 2)
	Doberman Pinscher (n, 2)	Other (n, 10 [1 each])
	Pug (n, 2)
	Other (n, 7 [1 each])
Cardiac medications at time of sampling	None	Furosemide (n, 14)
		Pimobendan (n, 14)
		ACE inhibitor (n, 12)
		Spironolactone (n, 10)
		Sildenafil (n, 2)